


PPACK II diTFA

Cat. No.:	HY-122543
CAS No.:	649748-23-2
Molecular Formula:	C ₂₉ H ₃₅ ClF ₆ N ₆ O ₇
Molecular Weight:	729.07
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (342.90 mM; Need ultrasonic)																			
	<table border="1"> <thead> <tr> <th rowspan="2">Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>1.3716 mL</td> <td>6.8581 mL</td> <td>13.7161 mL</td> </tr> <tr> <td>5 mM</td> <td>0.2743 mL</td> <td>1.3716 mL</td> <td>2.7432 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1372 mL</td> <td>0.6858 mL</td> <td>1.3716 mL</td> </tr> </tbody> </table>	Concentration	Mass			1 mg	5 mg	10 mg	1 mM	1.3716 mL	6.8581 mL	13.7161 mL	5 mM	0.2743 mL	1.3716 mL	2.7432 mL	10 mM	0.1372 mL	0.6858 mL	1.3716 mL
	Concentration		Mass																	
		1 mg	5 mg	10 mg																
1 mM	1.3716 mL	6.8581 mL	13.7161 mL																	
5 mM	0.2743 mL	1.3716 mL	2.7432 mL																	
10 mM	0.1372 mL	0.6858 mL	1.3716 mL																	
Preparing Stock Solutions																				
Please refer to the solubility information to select the appropriate solvent.																				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.85 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.85 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (2.85 mM); Clear solution 																			

BIOLOGICAL ACTIVITY

Description	PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor ^[1] .
In Vitro	PPACK II (0.62-50 μg/mL) diTFA significantly inhibits B-type natriuretic peptide (BNP) proteolysis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kentaro Takayama, et al. Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U. Biopolymers. 2016 Nov 4;106(4):440-5.

[2]. Alexander Belenky, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004 Feb;340(1-2):163-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA